Organovo Holdings, Inc. (ONVO)

[WHP03]

Samsara is simply part of ONVO's supply chain (access to quality product as needed). The ultimate 'selling shoves and Levi's scenario' is exactly what ONVO is going for with their plan to be doing 10s of millions of internal tox testing to prove out the technology and ultimately become a tissue factory supplied CRO's. That's when their primary purpose in life will be to 3D bioprint tissue in mass, while building disease models and constructing/selling therapeutic tissues (i.e. liver patches).

In my mind that last aspect of their business strategy (therapeutic tissues) demands a strong financial partner, or they're going to run into major capital issues that will be highly dilutive.

We're in the crossing the chasm stage of revenue generation from tissue tox testing. It's all about 'proving the dogs will eat the dog food', and the only meaningful evidence of that will be QoQ revenue growth.